Shanghai INT Medical expands into pulmonology with Broncus stake

Shanghai INT Medical Instruments Co., Ltd. has entered into a Subscription Agreement on October 10, 2025, to subscribe for 91,093,613 new shares in Broncus Holding Corporation for HK$283,301,136.43. The subscription price of HK$3.11 per share represents a 1.30% premium to Broncus's closing price on the Subscription Agreement date.

Upon completion, Shanghai INT Medical will hold approximately 14.38% of Broncus's enlarged issued share capital, signifying a strategic expansion into the non-vascular interventional field. Broncus, listed on the Stock Exchange, specializes in interventional pulmonology devices for lung disease navigation, diagnosis, and treatment.

This investment aims to further expand Shanghai INT Medical's strategic layout in non-vascular interventions. For the two years ended December 31, 2024, Broncus reported revenue of US$8.13m and a loss for the year of US$15.30m. As of June 30, 2025, Broncus's total assets were approximately US$165.67m. The financial results of Broncus will not be consolidated into the Group's accounts.